日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Incidence and predictors of HBsAg loss following addition of pegylated interferon Alfa-2b in chronic hepatitis B patients suppressed by nucleos(t)ide analogues: a multicenter, prospective, cohort study

在接受核苷(酸)类似物治疗且病毒载量得到抑制的慢性乙型肝炎患者中,加用聚乙二醇干扰素α-2b后乙型肝炎表面抗原(HBsAg)消失的发生率和预测因素:一项多中心、前瞻性队列研究

Zhao, Jing; Bian, Dandan; Xie, Dongying; Lv, Jun; Lin, Lanyi; Chen, Xinyue; Zhang, Liaoyun; Feng, Bo; Xu, Xiaoyuan; Lu, Fengmin; Zheng, Sujun

Liver fibrosis is closely linked with metabolic-associated diseases in patients with autoimmune hepatitis

肝纤维化与自身免疫性肝炎患者的代谢相关疾病密切相关。

Liu, Kehui; Feng, Mingyang; Chi, Wanqing; Cao, Zhujun; Wang, Xiaoyin; Ding, Yezhou; Zhao, Gangde; Li, Ziqiang; Lin, Lanyi; Bao, Shisan; Wang, Hui

Difficulty in differentiating liver injury from an immune checkpoint inhibitor from chemotherapy

难以区分免疫检查点抑制剂和化疗引起的肝损伤

Lou, Shike; Wang, Xiaoyin; Yuan, Fei; Zhao, Gangde; Feng, Mingyang; Ding, Yezhou; Lin, Lanyi; Liu, Kehui; Wang, Xiaolin; Chi, Wanqing; Wang, Hui

The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB

肝癌患者使用免疫检查点抑制剂的安全问题主要源于慢性乙型肝炎。

Lou, Shike; Cao, Zhujun; Chi, Wanqing; Wang, Xiaoyin; Feng, Mingyang; Lin, Lanyi; Ding, Yezhou; Liu, Kehui; Qu, Lihong; Zhao, Gangde; Bao, Shisan; Wang, Hui

The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China

中国原发性肝癌患者临床特征和代谢危险因素20年变化研究

Ding, Yezhou; Feng, Mingyang; Ma, Di; Zhao, Gangde; Wang, Xiaolin; An, Baoyan; Xu, Yumin; Lou, Shike; Lin, Lanyi; Xie, Qing; Liu, Kehui; Bao, Shisan; Wang, Hui

Sleep Duration Is Associated with Academic Achievement of Adolescent Girls in Mathematics

睡眠时长与青春期女孩的数学学业成绩相关

Lin, Lanyi; Somerville, Gail; Boursier, Johanne; Santisteban, Jose Arturo; Gruber, Reut

Correlation between hepatic human males absent on the first (hMOF) and viral persistence in chronic hepatitis B patients

首次肝细胞缺失(hMOF)与慢性乙型肝炎患者病毒持续存在之间的相关性

Chen, Liwen; Zhu, Chuanwu; Li, Fengdi; Wang, Yun; Bao, Rebecca; Cao, Zhujun; Xiang, Xiaogang; Yan, Lei; Lin, Lanyi; Zhao, Gangde; Xie, Qing; Bao, Shisan; Wang, Hui

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

在HBe抗原阴性的慢性乙型肝炎患者中,恩替卡韦联合治疗或换用聚乙二醇干扰素可改善HBsAg清除率。

Yan, Lei; Zhu, Chuanwu; Li, Jing; Chen, Liwen; Ding, Yezhou; Cao, Zhujun; Liu, Kehui; Lin, Lanyi; Tang, Weiliang; Xie, Qing; Xu, Yumin; Bao, Shisan; Wang, Hui

Circulating cell death biomarker: good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure

循环细胞死亡生物标志物:乙型肝炎病毒相关急性加重型慢性肝衰竭患者预后指标的良好候选者

Cao, Zhujun; Li, Fengdi; Xiang, Xiaogang; Liu, Kehui; Liu, Yuhan; Tang, Weiliang; Lin, Lanyi; Guo, Qing; Bao, Shisan; Xie, Qing; Wang, Hui

[Clinical profiles of circulating plasmacytoid dendritic cells in chronic hepatitis B patients in response to pegylated-interferon alfa-2a treatment].

[慢性乙型肝炎患者接受聚乙二醇干扰素α-2a治疗后循环浆细胞样树突状细胞的临床特征]。

Jia Nina, Lin Lanyi, Guo Simin, Zhao Gangde, Tang Weiliang, Xie Qing